sign in sign up
<<
Home , Acalabrutinib, Bosutinib, Carfilzomib, Cobimetinib, Dinutuximab, Elotuzumab

CYTOTOXIC (Alphabetical) CYTOTOXIC CHEMOTHERAPIES (Mech Action) Generic (Brand) Name Mechanism of Action Mechanism of Action Generic (Brand) Name 5-FU (5-) Alkylating agent (Treanda) 6-MP Antimetabolite Alkylating agent (Leukeran) (Vidaza) Antimetabolite Alkylating agent (Cytoxan) Bendamustine (Treanda) Alkylating agent Alkylating agent (Cytosar, Ara-C) (Velcade) inhibitors Alkylating agent (Fludara) (Xeloda) Antimetabolite Alkylating agent (Ifex) (Paraplatin) Platinum Antimetabolite 5-FU (5-fluorouracil)

Carfilzomib (Kyprolis) Proteasome inhibitors Antimetabolite 6-MP Chlorambucil (Leukeran) Alkylating agent Antimetabolite Azacitidine (Vidaza) (Platinol AQ) Platinum Antimetabolite Capecitabine (Xeloda) Cyclophosphamide (Cytoxan) Alkylating agent Antimetabolite (Halaven) Cytarabine (Cytosar, Ara-C) Alkylating agent Antimetabolite (Gemzar) nucleoside metabolic inhibitor and /cedazuridine (INQOVI) cytidine deaminase inhibitor Antimetabolite Hydroxyurea (Hydrea) Docetaxal (Taxotere) Antimetabolite (Ixempra) (Adriamycin) Antitumor Antimetabolite (Ellence) Antitumor antibiotic Antimetabolite Pemtrexed (Alimta) Eribulin (Halaven) Antimetabolite Antitumor antibiotic Doxorubicin (Adriamycin) (Vepesid, VP-16) Inhibitor Antitumor antibiotic Epirubicin (Ellence) Pegylated Liposomal doxorubicin Fludarabine (Fludara) Alkylating agent Antitumor antibiotic (Doxil) Gemcitabine (Gemzar) Antimetabolite Immunomodulating agents (Revlimid) Hydroxyurea (Hydrea) Antimetabolite Immunomodulating agents (Pomalyst) Ifosfamide (Ifex) Alkylating agent Immunomodulating agents Thalidomide (Thalomid) nucleoside metabolic inhibitor decitabine /cedazuridine (Camptosar) and cytidine deaminase inhibitor (INQOVI) Ixabepilone (Ixempra) Antimetabolite Platinum Carboplatin (Paraplatin) Lenalidomide (Revlimid) Immunomodulating agent Platinum Cisplatin (Platinol AQ) Pegylated Liposomal doxorubicin (Doxil) Antitumor antibiotic Platinum Lurbinectedin (Zepzelca) Polymerase transcription inhibitor Platinum Polymerase transcription Methotrexate Antimetabolite inhibitor Lurbinectedin (Zepzelca) (Novantrone) Topoisomerase Inhibitor Proteasome inhibitors Bortezomib (Velcade) Nab- (Abraxane) Taxane Proteasome inhibitors (Kyprolis) Nedaplatin Platinum Taxane Docetaxal (Taxotere) Oxaliplatin Platinum Taxane Nab-Paclitaxel (Abraxane) Paclitaxel (Taxol) Taxane Taxane Paclitaxel (Taxol) Pemtrexed (Alimta) Antimetabolite Topoisomerase Inhibitor Etoposide (Vepesid, VP-16) Pomalidomide (Pomalyst) Immunomodulating agent Topoisomerase Inhibitor Irinotecan Thalidomide (Thalomid) Immunomodulating agents Topoisomerase Inhibitor Mitoxantrone (Novantrone) Topoisomerase Inhibitor Topoisomerase Inhibitor Topotecan Vinca alkaloid Vinca alkaloid Vinblastine (Oncovin) Vinca alkaloid Vinca alkaloid Vincristine (Oncovin) (Navelbine) Vinca alkaloid Vinca alkaloid Vinorelbine (Navelbine)

SWOG Fall meeting 2020/ K Abueg updated 8/27/2020, Corrections: [email protected] TARGETED GENERIC (Brand) Names TARGET (ALPHABETICAL by TARGET) (Pemazyre) FGFR2 GENERIC (Brand) Names TARGET (Unituxin) GD2 (Alecensa) ALK (Tykerb) HER1/HER2 (Alunbrig) ALK (Nerlynx) HER1/HER2 (Zykadia) ALK ado- emtansine (Kadcyla) HER2 (Xalkori) ALK (Perjeta) HER2 (Venclexta) BCL-2 trastuzumab (Herceptin) HER2 belantamab (Blenrep) BCMA (Tukysa) HER2 (Bosulif) BCR-ABL fam--nxki (Enhertu) HER2 (Sprycel) BCR-ABL (Idhifa) IDH2 enzyme mesylate (Gleevec) BCR-ABL (Jakafi) JAK1/JAK2 (Tasigna) BCR-ABL riprettnib (Qinlock) KIT/PDGFR (Iclusig) BCR-ABL (Cotellic) MEK1/MEK2 (Tafinlar) BRAF (Mekinist) MEK1/MEK2 (Braftovi) BRAF V600E (Tabrecta) MET (Zelboraf) BRAF V600E (Afinitor) mTOR (Calquence) BTK (Torisel) mTOR (Imbruvica) BTK (Padcev) NECT-4 (Brukinsa) BTK selexinor (Xpovio) Nuclear Export -cxix (Monjuvi) CD19 (Zejula) PARP (Blincyto) CD-19/CD3 (Lynparza) PARP (Zevalin) CD20 (Rubraca) PARP (Gazyva) CD20 (Ayvakit) PDGFR-a (Arzerra) CD20 (Lartruvo) PDGFR-a (Rituxan) CD20 (Aliqopa) PI3K rituximab/hyaluronidase (Rituxan CD20 (Zydelig) PI3K Hycela) (Besponsa) CD22 bortezomib (Velcade) (Adcetris) CD30 carfilzomib (Kyprolis) proteasome inhibitor (Mylotarg) CD33 (Ninlaro) proteasome inhibitor (Darzalex) CD38 denosumab (Xgeva) RANKL -irfc (Sarclisa) CD38 (Retevmo) RET (Campath) CD52 (Empliciti) SLAMF7 (Verzenio) CDK 4/6 (Odomzo) (Ibrance) CDK 4/6 -hziy (Trodelvy) Trop-2 (Kisqali) CDK 4/6 (Avastin) VEGF (Gilotrif) EGFR (Votrient) VEGFR (Erbitux) EGFR (Stivarga) VEGFR (Tarceva) EGFR (Nexavar) VEGFR (Iressa) EGFR malate (Sutent) VEGFR () (Portrazza) EGFR (Inlyta) VEGFR (Cabometyx)/(Cometriq) VEGFR (multiple) (Tagrisso) EGFR (Cyramza) VEGFR2 (Vectibix) EGFR tazemetostat (Tazverik) EZH2 TARGETED Therapies/ (ALPHA by TARGET) Source: https://www.fda.gov/drugs/resources-information-approved-/hematologyoncology-cancer-approvals-safety-notifications Current as of 9/1/2020 Corrections: [email protected]

TARGETED Therapies TARGETED Therapies/ (ALPHABETICAL by NAME) ABC (ALPHABETICAL by DRUG NAME) ABC GENERIC (Brand) Names TARGET GENERIC (Brand) Names TARGET inotuzumab ozogamicin (Besponsa) CD22 abemaciclib (Verzenio) CDK 4 and 6 isatuximab-irfc (Sarclisa) CD38 acalabrutinib (Calquence) BTK ixazomib (Ninlaro) proteasome inhibitor ado- (Kadcyla) HER2 lapatinib (Tykerb) HER1/HER2 afatinib (Gilotrif) EGFR necitumumab (Portrazza) EGFR alectinib (Alecensa) ALK neratinib (Nerlynx) HER1/HER2 alemtuzumab (Campath) CD52 nilotinib (Tasigna) BCR-ABL avapritinib (Ayvakit) PDGFR-a niraparib (Zejula) PARP axitinib (Inlyta) VEGFR- obinutuzumab (Gazyva) CD20 bevacizumab (Avastin) VEGF ofatumumab (Arzerra) CD20 belantamab (Blenrep) BCMA olaparib (Lynparza) PARP blinatumomab (Blincyto) CD-19/CD3 olaratumab (Lartruvo) PDGFR-a bortezomib (Velcade) proteasome inhibitor osimertinib (Tagrisso) EGFR bosutinib (Bosulif) BCR-ABL palbociclib (Ibrance) CDK 4/6 brentuximab vedotin (Adcetris) CD30 panitumumab (Vectibix) EGFR brigatinib (Alunbrig) ALK pazopanib (Votrient) VEGFR cabozantinib (Cabometyx)/(Cometriq) VEGFR- pemigatinib (Pemazyre) FGFR2 capmatinib (Tabrecta) MET pertuzumab (Perjeta) HER2 carfilzomib (Kyprolis) proteasome inhibitor ponatinib (Iclusig) BCR-ABL; ceritinib (Zykadia) ALK ramucirumab (Cyramza) VEGFR2 cetuximab (Erbitux) EGFR regorafenib (Stivarga) VEGFR cobimetinib (Cotellic) MEK1/MEK2 ribociclib (Kisqali) CDK 4/6 copanlisib (Aliqopa) PI3K riprettnib (Qinlock) KIT/PDGFR crizotinib (Xalkori) ALK rituximab (Rituxan) CD20 dabrafenib (Tafinlar) BRAF V600E rituximab/hyaluronidase (Rituxan Hycela) CD20 daratumumab (Darzalex) CD38 rucaparib (Rubraca) PARP dasatinib (Sprycel) BCR-ABL ruxolitinib (Jakafi) JAK1/JAK2 denosumab (Xgeva) RANKL sacituzumab govitecan-hziy (Trodelvy) Trop-2 dinutuximab (Unituxin) GD2 selexinor (Xpovio) Nuclear Export elotuzumab (Empliciti) SLAMF7 selpercatinib (Retevmo) RET enasidenib (Idhifa) IDH2 enzyme sonidegib (Odomzo) Smoothened encorafenib (Braftovi) BRAF V600E sorafenib (Nexavar) VEGFR enfortumab vedotin (Padcev) NECT-4 sunitinib malate (Sutent) VEGFR erlotinib (Tarceva) EGFR tafasitamab-cxix (Monjuvi) CD19 everolimus (Afinitor) mTOR temsirolimus (Torisel) mTOR fam-trastuzumab deruxtecan-nxki (Enhertu) HER-2 tazemetostat (Tazverik) EZH2 gefitinib (Iressa) EGFR trametinib (Mekinist) MEK1/MEK2 gemtuzumab ozogamicin (Mylotarg) CD33 trastuzumab (Herceptin) HER2 ibritumomab tiuxetan (Zevalin) CD20 tucatinib (Tukysa) HER2 ibrutinib (Imbruvica) BTK vemurafenib (Zelboraf) BRAF V600E idelalisib (Zydelig) PI3K venetoclax (Venclexta) BCL-2 imatinib mesylate (Gleevec) BCR-ABL zanubrutinib (Brukinsa) BTK Source: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/hematologyoncology‐cancer‐approvals‐safety‐notifications Current as of 9/1/2020

corrections? [email protected]

HORMONAL/ ENDOCRINE THERAPIES (Alphabetical) HORMONAL/ ENDOCRINE THERAPIES (MOA)

Generic (Brand) Name Mechanism of Action Generic (Brand) Name Mechanism of Action anastrozole (Arimidex) Aromatase Inhibitor leuprorelin (Lupron) (GnRH) agonist abiraterone acetate (Zytiga) nonsteroidal antiandrogen bicalutamide (Casodex) Anti-Androgens bicalutamide (Casodex) Anti-Androgens flutamide (Eulexin) Anti-Androgens degarelix (Firmagon) LHRH Antagonists nilutamide (Nilandron) Anti-Androgens enzalutamide (Xtandi) nonsteroidal antiandrogen anastrozole (Arimidex) Aromatase Inhibitor exemestane (Aromasin) Aromatase Inhibitor exemestane (Aromasin) Aromatase Inhibitor flutamide (Eulexin) Anti-Androgens letrozole (Femara) Aromatase Inhibitor estrogen receptor (ER) fulvestrant (Faslodex) estrogen receptor (ER) antagonist fulvestrant (Faslodex) antagonist goserelin (Zoladex) LHRH Agonist goserelin (Zoladex) LHRH Agonist letrozole (Femara) Aromatase Inhibitor leuprolide (Lupron, Eligard) LHRH Agonist leuprolide (Lupron, Eligard) LHRH Agonist triptorelin (Trelstar) LHRH Agonist leuprorelin (Lupron) (GnRH) agonist degarelix (Firmagon) LHRH Antagonists megestrol (Megace) Progestins. abiraterone acetate (Zytiga) nonsteroidal antiandrogen nilutamide (Nilandron) Anti-Androgens enzalutamide (Xtandi) nonsteroidal antiandrogen Selective Estrogen Receptor raloxifene (Evista) megestrol (Megace) Progestins Modulator Selective Estrogen Receptor Selective Estrogen Receptor tamoxifen (Nolvadex) raloxifene (Evista) Modulator Modulator Selective Estrogen Receptor triptorelin (Trelstar) LHRH Agonist tamoxifen (Nolvadex) Modulator

IMMUNOTHERAPY (Alphabetical) (Mechanism of Action) Generic (Brand) Name Mechanism of Action Generic (Brand) Name Mechanism of Action (Tecentriq) Anti-PD-L1 (Yervoy) Anti-CTLA4 (Bevancio) Anti-PD-L1 camiplimab (Libtayo) Anti-PD1 brexucabtagene autoleucel CD-19 T cell (Opdivo) Anti-PD1 (Tecartus) (Imfinzi) Anti-PD-L1 (Keytruda) Anti-PD1 ipilimumab (Yervoy) Anti-CTLA4 atezolizumab (Tecentriq) Anti-PD-L1 nivolumab (Opdivo) Anti-PD1 avelumab (Bevancio) Anti-PD-L1 pembrolizumab (Keytruda) Anti-PD1 durvalumab (Imfinzi) Anti-PD-L1 camiplimab (Libtayo) Anti-PD1 brexucabtagene autoleucel (Tecartus) CD-19 T cell

SUPPORTIVE (Alphabetical) SUPPORTIVE (Mechanism of Action) Generic (Brand) Name Mechanism of Action Generic (Brand) Name Mechanism of Action alendronate (Fosamax) alendronate (Fosamax) Bisphosphonate Granulocyte colony-stimulating factor (Neupogen) (G-CSF or GCSF), Zoledronic Acid (Zometa/ Reclast) Bisphosphonate Granulocyte colony-stimulating factor filgrastim biosimilar (Zarxio) (G-CSF or GCSF), ibandronate (Boniva) Bisphosphonate ibandronate (Boniva) Bisphosphonate pamidronate (Aredia) Bisphosphonate Granulocyte colony-stimulating factor pamidronate (Aredia) Bisphosphonate filgrastim (Neupogen) (G-CSF or GCSF), Granulocyte colony-stimulating factor Granulocyte colony-stimulating factor (Neulasta) (G-CSF or GCSF), filgrastim biosimilar (Zarxio) (G-CSF or GCSF), pegfilgrastim biosimilar (Fulphila, Granulocyte colony-stimulating factor Granulocyte colony-stimulating factor Udenyca) (G-CSF or GCSF), pegfilgrastim (Neulasta) (G-CSF or GCSF), Granulocyte –macrophage colony-stimulating pegfilgrastim biosimilar (Fulphila, Granulocyte colony-stimulating factor (Leukine) factor (GM-CSF) Udenyca) (G-CSF or GCSF), Granulocyte –macrophage colony- zoledronic Acid (Zometa/ Reclast) Bisphosphonate sargramostim (Leukine) stimulating factor (GM-CSF)

Source: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/hematologyoncology‐cancer‐approvals‐safety‐notifications Current as of 9/1/2020

corrections? [email protected] Adjuvant Adjuvant CURATIVE surgery treatment AFTER

NEOadjugnat Neoadjuvant Treatment CURATIVE surgery BEFORE

DE NOVO Diagnosed at DE NOVO Stage IV METASTATIC metastatic treatment 1st line

Complete Recurrent RECURRENT / Response after METASTATIC prior treatment

nd >= 2 line 1st line tx for Progression 2nd line (Palliative) metastatic disease

Intense therapy INDUCTION & to reduce heme Disease Response CONSOLIDATION CONSOLIDATION or lung tumor (no progression) to assure stability burden

Intense therapy MAINTENANCE resulting in tumor MAINTENANCE long term stability